Patients are characterized by severe progressive hyperglycemia and beta-cell dysfunction, with impaired glucose-stimulated insulin secretion response by pancreatic beta-cells in contrast to insulin resistance by target tissues displayed by most NIDDM patients.1,2. This evidence concerns the gene INS and type 2 diabetes mellitus.